Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptor, ErbB-2”

1,051 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,051 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Not applicableUnknownNCT03979911
What this trial is testing

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsHER-2 Gene Amplification
University Hospital, Brest 63
Early research (Phase 1)Active Not RecruitingNCT04511871
What this trial is testing

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Who this might be right for
Solid TumorGastric CancerBreast Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 12
Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Early research (Phase 1)Temporarily pausedNCT05076591
What this trial is testing

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerAdvanced Gastric Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 135
Testing effectiveness (Phase 2)Ended earlyNCT03241810
What this trial is testing

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Elevation Oncology 22
Large-scale testing (Phase 3)Study completedNCT01564056
What this trial is testing

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Who this might be right for
Breast Cancer
UNICANCER 1,989
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Early research (Phase 1)Study completedNCT01526473
What this trial is testing

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

Who this might be right for
HER2+ Cancer
H. Kim Lyerly 22
Next Page